Recursion Pharma Files Proxy Materials

TL;DR

Recursion Pharma dropped proxy docs, shareholder meeting incoming.

AI Summary

Recursion Pharmaceuticals, Inc. filed a Definitive Additional Materials proxy statement on October 30, 2024. This filing relates to the company's solicitation of proxies for its upcoming shareholder meeting. The company is based in Salt Lake City, UT, and operates in the biological products sector.

Why It Matters

This filing indicates Recursion Pharmaceuticals is actively engaging with shareholders regarding corporate matters, which could impact future strategic decisions and governance.

Risk Assessment

Risk Level: low — This filing is a standard proxy statement, not indicating any immediate financial or operational risks.

Key Players & Entities

• Recursion Pharmaceuticals, Inc. (company) — Registrant
• Salt Lake City, UT (location) — Company Headquarters
• 0001601830-24-000184.txt (document) — Filing Identifier

FAQ

Filing Documents

• recursion-solicitationmate.htm (DEFA14A) — 29KB
• 0001601830-24-000184.txt ( ) — 30KB

Forward-Looking Statements

Forward-Looking Statements This document contains information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the timing of the business updates and report on its third-quarter financial results the occurrence and timing of an investor call the anticipated closing of the proposed business combination with Exscientia and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as "plan," "will," "expect," "anticipate," "intend," "believe," "potential," "continue," and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors our ability to leverage and enhance our drug discovery platform our ability to obtain financing for development activities and other corporate purposes the success of our collaboration activities our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates our ability to obtain, maintain, and enforce intellectual property protections cyberattacks or other disruptions to our technology systems our ability to attract, motivate, and retain key employees and manage our growth inflation and other macroeconomic issues and other risks and uncertainties such as those described under the heading "Risk Factors" in our filings with the U.S. Securities and Exchange Commission (the "SEC"), including in the definitive joint proxy statement related to the proposed

View Full Filing

View this DEFA14A filing on SEC EDGAR